A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device

NCT01791244 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis
Relapsing-Remitting

Interventions

DRUG: Rebif®

Sponsor

Merck KGaA, Darmstadt, Germany